Bayer makes first move into condensates

DetailsNat Biotechnol. 2020 Jan;38(1):5. doi: 10.1038/s41587-019-0386-6.
Published January 30, 2020
DOI10.1038/s41587-019-0386-6
Topics
Keywords
Source Read whole story

German pharma Bayer has signed a $100 million deal with Dewpoint Therapeutics to jointly pursue biomolecular condensates for drug discovery. The companies will combine Dewpoint’s condensates expertise with Bayer’s small-molecules library to discover drugs for heart diseases and gynecological indications…

Join the conversation

Create an Account or Sign In to comment.